Stuart Therapeutics

Executive Summary

Stuart Therapeutics is a private, US-based biotechnology company founded in 2018, focused on developing small molecule therapeutics. The company has achieved a significant milestone with its stage designation of 'Approved', suggesting it has obtained regulatory approval for at least one product. While specific details on its pipeline and financials are limited, the company operates in the small molecules category and is headquartered in Wilmington. Stuart Therapeutics is not actively hiring through external job boards, indicating a lean operational structure. The lack of disclosed pipeline or commercial product data suggests a need for further transparency regarding its approved product and future development plans.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for New Indication50% success
• Q2 2026Partnership or Licensing Deal30% success
• TBDClinical Trial Results for Pipeline Asset40% success